BioLargo director receives new stock option grants

BIOLARGO, INC. director Dennis E. Marshall reported two stock option grants on June 30, 2026.

Rhea-AI Filing Summary

BIOLARGO, INC. director Dennis E. Marshall reported two stock option grants on June 30, 2026. He received an option for 115,741 shares of common stock at an exercise price of $0.1135 per share, granted to replace a prior 22,500-share option that expired unexercised.

He also received a second option for 198,238 shares at the same $0.1135 exercise price as payment for $18,750 of board fees under the 2024 Equity Incentive Plan. Following these awards, his reported derivative holdings in options totaled 5,639,476 options.

Insider Trade Summary

Grant/Award: 313,979 shares

Grant/Award 2 txns

Insider Marshall Dennis E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock	198,238	$0.00	$0.00
Grant/Award	Option to Purchase Common Stock	115,741	$0.00	$0.00

Holdings After Transaction: Option to Purchase Common Stock — 11,444,150 contracts (Direct)

Footnotes (3)

1. F1. This Option was granted to Reporting Person to replace an option to purchase 22,500 shares that had been issued to compensate Reporting Person for services to the Issuer and had expired unexercised due to a discrepancy between the original exercise price and Issuer's current stock price, pursuant to plan adopted by the Issuer's Compensation Committee.
2. F2. Total reflects the expiration of options to purchase 22,500 shares that expired June 30, 2026.
3. F3. This Option was issued to Reporting Person as payment for $18,750 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan. The number of shares in the Option is equal to the amount of fees due divided by the exercise price of the Option.

Key Figures

First option grant size: 115,741 options Second option grant size: 198,238 options Exercise price per share: $0.1135/share +5 more

8 metrics

First option grant size 115,741 options Option to purchase common stock granted June 30, 2026

Second option grant size 198,238 options Option to purchase common stock granted as board fee payment

Exercise price per share $0.1135/share Exercise price for both option grants

Board fees paid in options $18,750 Fees for most recent quarterly period paid via option grant

Options underlying first grant 165,198 shares Underlying common stock for first option grant

Options underlying second grant 198,238 shares Underlying common stock for second option grant

Total options after transactions 5,639,476 options Total derivative holdings following June 30, 2026 transactions

Expired option size 22,500 options Prior option that expired unexercised on June 30, 2026

Key Terms

Option to Purchase Common Stock, exercise price, 2024 Equity Incentive Plan, derivative, +1 more

5 terms

Option to Purchase Common Stock financial

"security_title: Option to Purchase Common Stock"

exercise price financial

"a discrepancy between the original exercise price and Issuer's current stock price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

2024 Equity Incentive Plan financial

"pursuant to the Issuer's 2024 Equity Incentive Plan"

derivative financial

"transaction_type: derivative"

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

board of directors financial

"services on its board of directors for the most recently completed quarterly period"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioLargo (BLGO) director Dennis E. Marshall report in this Form 4?

Dennis E. Marshall reported receiving two grants of options to purchase BioLargo common stock. One award replaced an expired option, and the other compensated him for recent board service fees, reflecting routine director compensation rather than open-market share purchases or sales.

How many BioLargo (BLGO) stock options did the director receive and at what exercise price?

He received options covering 115,741 shares and 198,238 shares of BioLargo common stock. Both option grants carry an exercise price of $0.1135 per share, defining the cost he must pay per share if he later chooses to exercise the options.

Were any of the BioLargo (BLGO) options granted to replace expired awards?

Yes. One option grant for 115,741 shares was issued to replace a prior option for 22,500 shares that expired unexercised. The replacement followed a compensation committee plan addressing a discrepancy between the original exercise price and BioLargo’s then-current stock price.

How were Dennis E. Marshall’s board fees at BioLargo (BLGO) paid according to this filing?

The filing states an option for 198,238 shares was issued as payment for $18,750 in board of directors fees. The number of option shares equals the fees due divided by the $0.1135 exercise price, under BioLargo’s 2024 Equity Incentive Plan.

What are Dennis E. Marshall’s total reported BioLargo (BLGO) option holdings after these grants?

After the June 30, 2026 option awards, his total reported derivative holdings in options to purchase BioLargo common stock were 5,639,476. This figure reflects the net effect of the new grants and the expiration of a prior 22,500-share option on the same date.

Do the reported BioLargo (BLGO) option grants involve open-market buying or selling of shares?

No. Both transactions are categorized as grant/award acquisitions of options, not open-market trades. One option replaced an expired award, and the other compensated board service fees, so there is no indicated market purchase or sale of common shares in this Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 06:21 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Marshall Dennis E

(Last) (First) (Middle)

14921 CHESTNUT ST.

(Street)

WESTMINSTER CALIFORNIA 92683

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOLARGO, INC. [ BLGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$0.1135	06/30/2026		A		198,238		06/30/2026	06/30/2036	Common Stock	198,238	(1)	5,639,476(2)	D
Option to Purchase Common Stock	$0.1135	06/30/2026		A		115,741		06/30/2026	06/30/2036	Common Stock	165,198	(3)	5,804,674	D

Explanation of Responses:

1. This Option was granted to Reporting Person to replace an option to purchase 22,500 shares that had been issued to compensate Reporting Person for services to the Issuer and had expired unexercised due to a discrepancy between the original exercise price and Issuer's current stock price, pursuant to plan adopted by the Issuer's Compensation Committee.

2. Total reflects the expiration of options to purchase 22,500 shares that expired June 30, 2026.

3. This Option was issued to Reporting Person as payment for $18,750 in fees due to Reporting Person by Issuer in exchange for services on its board of directors for the most recently completed quarterly period, pursuant to the Issuer's 2024 Equity Incentive Plan. The number of shares in the Option is equal to the amount of fees due divided by the exercise price of the Option.

	/s/ John R. Browning, attorney-in-fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)